Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple ...

Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat patients early after relapse.

Radiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, muscle-invasive bladder cancer, according to results of a new phase III randomized trial.

Recovery from addiction is a challenging journey, filled with both triumphs and setbacks. For individuals seeking long-term sobriety, relapse can be a disheartening reality. However, recent findings ...

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: Many patients, including those whose cancer goes into ...

HBV, hepatitis B Researchers analyzed data from patients with chronic hepatitis B to identify predictors of relapse in those who discontinued NAs and determined if existing rules for stopping NA ...

(WISH) — Chimeric antigen receptor T-cell therapy is revolutionizing the treatment of certain blood cancers. CAR T-cell therapy uses genetically enhanced versions of a patient’s own cancer-fighting ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...